Gynecologic Cancers

Latest News

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

July 25th 2025

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.

Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype
Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype

July 14th 2025

The use of 68Ga-Pentixafor compliments fluorodeoxyglucose and had no correlation with CXCR4 immunohistochemistry.
CXCR4 Expression in Gynecologic Malignancies Correlates With OS

June 23rd 2025

More than 80% of patients who were screened for cervical cancer and provided with a self-collection kit did so by utilizing the kit.
Self-Collection May Help Increase Cervical Cancer Screening Rates

June 14th 2025

Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer
Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer

June 4th 2025

Video Series
Video Interviews
Podcasts
Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.
Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

More News